Developer docs
API playgroundTry for free, no card

Search company profiles

Hummingbird Bioscience

Full company profile

uuid0000b8o

Namestring
Hummingbird Bioscience
Legal namestring
Hummingbird Bioscience Ltd.
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Hummingbird Bioscience uses systems biology to develop insights into disease biology and applies computationally guided platforms to discover and engineer breakthrough biotherapeutics. The company is pursuing a broad pipeline of first drug candidates across multiple challenging targets with strong biological validation and disease association, including lead assets: HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, for the treatment of cancer. Hummingbird has established strategic collaborations with Cancer Research UK and Amgen, and has been awarded a product development grant from the Cancer Prevention and Research Institute of Texas.

Short descriptiontext

Hummingbird Bioscience focuses on the discovery and early development of oncology drugs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWoodlands, Singapore
HQ citystring
Woodlands
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision biotherapeutics, antibody therapeutics discovery, antibody-drug conjugates, oncology drug development, AI antibody discovery
Industry2 codes
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Licensing Agreements
TypeLicensing Royalties
Description

Hummingbird licenses its proprietary antibody programs to partner companies for further development and commercialization, receiving upfront payments, milestone payments, and royalties.

finance.yahoo.com
2Strategic Investments
TypeLicensing Royalties
Description

Company participates as an investor in complementary biotech companies, receiving equity stakes and potential future returns.

vcnewsdaily.com
3Co-development Partnerships
TypeLicensing Royalties
Description

Collaborative development arrangements where Hummingbird contributes its technology platforms and drug candidates while partners provide funding, development expertise, and commercialization capabilities.

hummingbirdbioscience.com
4Research Grants
TypeLicensing Royalties
Description

Non-dilutive funding from government agencies such as Cancer Prevention and Research Institute of Texas (CPRIT) to support specific research and clinical development programs.

hummingbirdbioscience.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1mAbPredictAI
Description

AI-powered computational biology platform for integrated analysis of multidisciplinary data to produce validated insights into disease biology and predict optimal epitopes for antibody development.

hummingbirdbioscience.com
+1 more record
Core offering1 text field

Hummingbird Bioscience discovers and develops precision antibody-based therapeutics, including monoclonal antibodies and antibody-drug conjugates, for hard-to-treat cancers and autoimmune diseases. Its pipeline is powered by a proprietary Rational Antibody Discovery platform combining AI-driven computational biology (mAbPredictAI) with immunoengineering (mAbHits Abvantage), and an ADC platform using proprietary linker-payload technologies. The company monetizes its pipeline through out-licensing and co-development partnerships with pharmaceutical and biotech companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • More than 80% tumor growth inhibition observed in preclinical models with common HER3 mutations
+2 more records
Product overview1 text field

Hummingbird Bioscience is a data-driven precision biotherapeutics company developing a portfolio of clinical-stage antibody-based therapeutics for hard-to-treat diseases, particularly cancer. The company's pipeline includes HMBD-001 (anti-HER3 monoclonal antibody), HMBD-002 (anti-VISTA monoclonal antibody licensed to Percheron Therapeutics), and HMBD-501 (HER3-targeting ADC), alongside partnered programs (HMBD-802, HMBD-803, HMBD-804 licensed to Callio Therapeutics, and HMBD-011). These programs are powered by the company's proprietary Rational Antibody Discovery (RAD) platform, which integrates AI-powered computational biology (mAbPredictAI) with immunoengineering capabilities (mAbHits Abvantage), and an ADC Platform utilizing proprietary linker-payload technologies for next-generation antibody-drug conjugate development.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Percheron Therapeutics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-26
Description

Percheron Therapeutics licensed HMBD-002 (Phase II-ready anti-VISTA monoclonal antibody) from Hummingbird Bioscience in June 2025. Percheron is advancing the asset through Phase II trials targeting triple-negative breast cancer as the priority indication, with Q4 2026 trial commencement targeted. Percheron completed GMP drug substance production in June 2026 under the licensing agreement.

finance.yahoo.com
2Callio Therapeutics
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Callio Therapeutics licensed three ADC programs from Hummingbird Bioscience: HMBD-802 (HER2-targeted dual-payload ADC), HMBD-803, and HMBD-804 (both undisclosed targets). These programs are partnered as part of Callio's ADC pipeline.

hummingbirdbioscience.com
3Undisclosed Partner
Strategic tierUndisclosedTypeStrategic or Co-development Partner
Description

HMBD-011 (VH4-34 targeting monoclonal antibody) is licensed to an undisclosed party for development in oncology and autoimmune indications.

hummingbirdbioscience.com
4Geisel School of Medicine at Dartmouth
Strategic tierModerateTypeStrategic or Co-development Partner
Description

Hummingbird Bioscience and Dartmouth's Geisel School of Medicine co-host the annual Virtual VISTA Symposium, bringing together researchers to discuss VISTA biology and therapeutic potential.

hummingbirdbioscience.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1BeiGene
TypeBroad incumbent
Description

Global oncology-focused biotechnology company developing both small molecules and antibody therapeutics including ADCs. While much larger and more diversified, BeiGene shares Hummingbird's oncology focus and antibody-based therapeutic approach.

2Compass Therapeutics
TypeDirect peer
Description

Clinical-stage antibody oncology company developing both naked antibodies and ADCs with platform-driven discovery. Compass's pipeline structure (multiple antibody programs in oncology, licensing-driven business model) closely parallels Hummingbird's approach.

3AbCellera Biologics
TypeDirect peer
Description

Antibody discovery platform company combining AI/computational biology with high-throughput wet lab capabilities to generate therapeutic antibodies. Both companies operate technology-platform business models monetizing antibody discovery through partnerships.

4Schrödinger
TypeDirect peer
Description

Computational drug discovery platform company using physics-based modeling and AI for drug design across multiple modalities. Both companies leverage computational biology as a core differentiator for therapeutic discovery, though Schrödinger spans small molecules and biologics.

5Pyxis Oncology
TypeDirect peer
Description

Clinical-stage oncology company developing antibody-drug conjugates and immunotherapies. Pyxis's ADC pipeline and oncology focus (including tumor-microenvironment targeting) overlaps directly with Hummingbird's HMBD-501 and partnered ADC programs.

6Recursion Pharmaceuticals
TypeDirect peer
Description

AI-driven drug discovery company combining high-throughput biology, chemistry, and machine learning to identify novel therapeutics. Similar to Hummingbird's mAbPredictAI approach, Recursion uses AI for target identification and drug design, though with broader therapeutic scope.

7Exscientia
TypeDirect peer
Description

AI-native drug discovery company combining patient biology data with AI for precision medicine design. Both companies emphasize integration of AI with patient biology for precision therapeutics, though Exscientia focuses more on small molecules.

8Bolt Biotherapeutics
TypeDirect peer
Description

Clinical-stage immuno-oncology company developing antibody-based therapeutics including next-generation ADCs and immune-stimulating conjugates. Bolt's pipeline and oncology focus directly parallel Hummingbird's HMBD-001 and ADC programs.

9ProfoundBio
TypeDirect peer
Description

Clinical-stage biotech developing next-generation ADCs with proprietary linker-payload technologies for oncology. ProfoundBio's ADC platform approach — combining novel payloads with antibody targeting — directly competes with Hummingbird's HMBD-802/501 ADC programs.

10Dragonfly Therapeutics
TypeDirect peer
Description

Biotechnology company developing antibody-based immunotherapies for cancer and autoimmune diseases using proprietary platform technology. Dragonfly's platform-driven antibody approach (TriNKETs, cytokine therapies) parallels Hummingbird's platform-based discovery model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors23 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hummingbird Bioscience

Hummingbird Bioscience focuses on the discovery and early development of oncology drugs.

What Hummingbird Bioscience does

Hummingbird Bioscience uses systems biology to develop insights into disease biology and applies computationally guided platforms to discover and engineer breakthrough biotherapeutics. The company is pursuing a broad pipeline of first drug candidates across multiple challenging targets with strong biological validation and disease association, including lead assets: HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, for the treatment of cancer. Hummingbird has established strategic collaborations with Cancer Research UK and Amgen, and has been awarded a product development grant from the Cancer Prevention and Research Institute of Texas.

Hummingbird Bioscience firmographics

Firmographics
Name
Hummingbird Bioscience
Legal name
Hummingbird Bioscience Ltd.
Website
https://hummingbirdbioscience.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Hummingbird Bioscience focuses on the discovery and early development of oncology drugs.
Ownership category
akta.pro rank

Hummingbird Bioscience industry classification

Industry
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Precision biotherapeutics
  • Antibody therapeutics discovery
  • Antibody-drug conjugates
  • Oncology drug development
  • AI antibody discovery

Where Hummingbird Bioscience is headquartered

Location

Headquarters

HQ city
Woodlands
HQ country
Singapore
HQ region
Asia

Offices2 records

Markets served

Hummingbird Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing

Revenue model

  1. Licensing Agreements: Hummingbird licenses its proprietary antibody programs to partner companies for further development and commercialization, receiving upfront payments, milestone payments, and royalties.
  2. Strategic Investments: Company participates as an investor in complementary biotech companies, receiving equity stakes and potential future returns.
  3. Co-development Partnerships: Collaborative development arrangements where Hummingbird contributes its technology platforms and drug candidates while partners provide funding, development expertise, and commercialization capabilities.
  4. Research Grants: Non-dilutive funding from government agencies such as Cancer Prevention and Research Institute of Texas (CPRIT) to support specific research and clinical development programs.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Hummingbird Bioscience product offering

Product offering

Core offering

Hummingbird Bioscience discovers and develops precision antibody-based therapeutics, including monoclonal antibodies and antibody-drug conjugates, for hard-to-treat cancers and autoimmune diseases. Its pipeline is powered by a proprietary Rational Antibody Discovery platform combining AI-driven computational biology (mAbPredictAI) with immunoengineering (mAbHits Abvantage), and an ADC platform using proprietary linker-payload technologies. The company monetizes its pipeline through out-licensing and co-development partnerships with pharmaceutical and biotech companies.

Product overview

Hummingbird Bioscience is a data-driven precision biotherapeutics company developing a portfolio of clinical-stage antibody-based therapeutics for hard-to-treat diseases, particularly cancer. The company's pipeline includes HMBD-001 (anti-HER3 monoclonal antibody), HMBD-002 (anti-VISTA monoclonal antibody licensed to Percheron Therapeutics), and HMBD-501 (HER3-targeting ADC), alongside partnered programs (HMBD-802, HMBD-803, HMBD-804 licensed to Callio Therapeutics, and HMBD-011). These programs are powered by the company's proprietary Rational Antibody Discovery (RAD) platform, which integrates AI-powered computational biology (mAbPredictAI) with immunoengineering capabilities (mAbHits Abvantage), and an ADC Platform utilizing proprietary linker-payload technologies for next-generation antibody-drug conjugate development.

Differentiator

Problem solved

Functional benefit

Brands

  • mAbPredictAI: AI-powered computational biology platform for integrated analysis of multidisciplinary data to produce validated insights into disease biology and predict optimal epitopes for antibody development.
  • mAbHits Abvantage™

Quantifiable outcome

  • More than 80% tumor growth inhibition observed in preclinical models with common HER3 mutations
  • +2 more outcomes

Companies that use Hummingbird Bioscience

Customer profile

Named customers2 records

Segments4 records

Hummingbird Bioscience technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Hummingbird Bioscience partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, undisclosed and moderate.

  • Percheron TherapeuticscoreStrategic or Co-development Partner · 26 June 2025Percheron Therapeutics licensed HMBD-002 (Phase II-ready anti-VISTA monoclonal antibody) from Hummingbird Bioscience in June 2025. Percheron is advancing the asset through Phase II trials targeting triple-negative breast cancer as the priority indication, with Q4 2026 trial commencement targeted. Percheron completed GMP drug substance production in June 2026 under the licensing agreement.
  • Callio TherapeuticscoreStrategic or Co-development PartnerCallio Therapeutics licensed three ADC programs from Hummingbird Bioscience: HMBD-802 (HER2-targeted dual-payload ADC), HMBD-803, and HMBD-804 (both undisclosed targets). These programs are partnered as part of Callio's ADC pipeline.
  • Undisclosed PartnerundisclosedStrategic or Co-development PartnerHMBD-011 (VH4-34 targeting monoclonal antibody) is licensed to an undisclosed party for development in oncology and autoimmune indications.
  • Geisel School of Medicine at DartmouthmoderateStrategic or Co-development PartnerHummingbird Bioscience and Dartmouth's Geisel School of Medicine co-host the annual Virtual VISTA Symposium, bringing together researchers to discuss VISTA biology and therapeutic potential.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Hummingbird Bioscience competitors and assessment

Company assessment

Broad incumbents

  • BeiGene: Global oncology-focused biotechnology company developing both small molecules and antibody therapeutics including ADCs. While much larger and more diversified, BeiGene shares Hummingbird's oncology focus and antibody-based therapeutic approach.

Direct peers

  • Compass Therapeutics: Clinical-stage antibody oncology company developing both naked antibodies and ADCs with platform-driven discovery. Compass's pipeline structure (multiple antibody programs in oncology, licensing-driven business model) closely parallels Hummingbird's approach.
  • AbCellera Biologics: Antibody discovery platform company combining AI/computational biology with high-throughput wet lab capabilities to generate therapeutic antibodies. Both companies operate technology-platform business models monetizing antibody discovery through partnerships.
  • Schrödinger: Computational drug discovery platform company using physics-based modeling and AI for drug design across multiple modalities. Both companies leverage computational biology as a core differentiator for therapeutic discovery, though Schrödinger spans small molecules and biologics.
  • Pyxis Oncology: Clinical-stage oncology company developing antibody-drug conjugates and immunotherapies. Pyxis's ADC pipeline and oncology focus (including tumor-microenvironment targeting) overlaps directly with Hummingbird's HMBD-501 and partnered ADC programs.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology, chemistry, and machine learning to identify novel therapeutics. Similar to Hummingbird's mAbPredictAI approach, Recursion uses AI for target identification and drug design, though with broader therapeutic scope.
  • Exscientia: AI-native drug discovery company combining patient biology data with AI for precision medicine design. Both companies emphasize integration of AI with patient biology for precision therapeutics, though Exscientia focuses more on small molecules.
  • Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing antibody-based therapeutics including next-generation ADCs and immune-stimulating conjugates. Bolt's pipeline and oncology focus directly parallel Hummingbird's HMBD-001 and ADC programs.
  • ProfoundBio: Clinical-stage biotech developing next-generation ADCs with proprietary linker-payload technologies for oncology. ProfoundBio's ADC platform approach — combining novel payloads with antibody targeting — directly competes with Hummingbird's HMBD-802/501 ADC programs.
  • Dragonfly Therapeutics: Biotechnology company developing antibody-based immunotherapies for cancer and autoimmune diseases using proprietary platform technology. Dragonfly's platform-driven antibody approach (TriNKETs, cytokine therapies) parallels Hummingbird's platform-based discovery model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Hummingbird Bioscience social profiles

Digital presence

Hummingbird Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hummingbird Bioscience leadership team

Management profile

Number of profiles

Hummingbird Bioscience subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Hummingbird Bioscience funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors23 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hummingbird Bioscience M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hummingbird Bioscience

What does Hummingbird Bioscience do?

Hummingbird Bioscience discovers and develops precision antibody-based therapeutics, including monoclonal antibodies and antibody-drug conjugates, for hard-to-treat cancers and autoimmune diseases. Its pipeline is powered by a proprietary Rational Antibody Discovery platform combining AI-driven computational biology (mAbPredictAI) with immunoengineering (mAbHits Abvantage), and an ADC platform using proprietary linker-payload technologies. The company monetizes its pipeline through out-licensing and co-development partnerships with pharmaceutical and biotech companies.

Is Hummingbird Bioscience a public or private company?

Hummingbird Bioscience is a private company. It is currently operating.

When was Hummingbird Bioscience founded?

Hummingbird Bioscience was founded in 2014. It employs 51 to 100 people.

Where is Hummingbird Bioscience based?

Hummingbird Bioscience is headquartered in Woodlands, Singapore, in the Asia region.

How does Hummingbird Bioscience make money?

Four revenue lines are on record. Licensing Agreements are the primary driver. The others are strategic Investments, co-development Partnerships and research Grants.

Who are Hummingbird Bioscience's main competitors?

BeiGene is listed as a broad incumbent. Direct peers are Compass Therapeutics, AbCellera Biologics, Schrödinger, Pyxis Oncology, Recursion Pharmaceuticals, Exscientia, Bolt Biotherapeutics, ProfoundBio and Dragonfly Therapeutics.

Does Hummingbird Bioscience have an API?

No public API is recorded for Hummingbird Bioscience.

What industry is Hummingbird Bioscience in?

Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageHummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell CancersHummingbird Bioscience announced the first patient dosed in Phase II of HMBD-001 plus cetuximab for advanced squamous cell cancers. The anti-HER3 antibody's recommended doses were identified based on safety, tolerability, and preliminary efficacy. The company plans to continue using its AIMM platform to enrich patient populations.BioSpaceHummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell CancersHummingbird Bioscience announced the first patient dosed in Phase II of HMBD-001-103, an anti-HER3 antibody combined with cetuximab for advanced squamous cell cancers. The trial is recruiting across multiple countries, and the FDA approved an IND application. The company plans to continue using its AIMM platform to enrich patient populations.YahooHummingbird Bioscience Appoints Dr. James Garner as PresidentHummingbird Bioscience appointed Dr. James Garner as President, joining CEO Piers Ingram. Garner brings over two decades of experience, including CEO roles at Percheron and Kazia Therapeutics, and has overseen more than 30 product approvals. He will lead the company's growth and pipeline advancement.FinancialContent Business PageHummingbird Bioscience Appoints Dr. James Garner as PresidentHummingbird Bioscience appointed Dr. James Garner as President, joining CEO Piers Ingram. Garner brings over two decades of experience, including CEO roles at Percheron and Kazia Therapeutics, and has overseen more than 30 product approvals. He will lead the company's growth and pipeline advancement.BioSpaceHummingbird Bioscience Appoints Dr. James Garner as PresidentHummingbird Bioscience appointed Dr. James Garner as President, joining CEO Piers Ingram. Garner brings over two decades of experience, including roles at Biogen, Takeda, and Sanofi, and previously led Percheron Therapeutics and Kazia Therapeutics. He will advance Hummingbird's AI-first drug discovery platform and pipeline.Prime Minister's Office SingaporeDPM Heng Swee Keat at Opening of Hummingbird Bioscience at Galen BuildingDPM Heng Swee Keat opened Hummingbird Bioscience's new 40,000-square-foot facility at the Galen Building on 23 September 2022. The company, a precision biotherapeutics start-up, has grown to 150 employees and secured US$125 million in Series C funding last year. He highlighted Singapore's biotech ecosystem, including S$25 billion in government investment.YahooVISTA Inhibitor Market Insights Report 2026 | Featuring Profiles of Aurigene Discovery Technologies, Curis, Hummingbird Bioscience, Kineta, PharmAbcineResearchAndMarkets.com added a report on the global VISTA inhibitor market, covering drivers, risks, clinical milestones, regional innovation and competitive positioning. The report notes no VISTA inhibitor has received regulatory approval as of June 2026, with candidates in clinical development across oncology indications. It assesses the possibility of the first approval by 2029.Straits ResearchImmune Checkpoint Inhibitors Market Size, Share & Growth, 2034Bristol Myers Squibb's Opdualag became the first next-generation immune checkpoint inhibitor with global regulatory approval (FDA March 2022, European Commission September 2022), combining nivolumab with relatlimab for unresectable or metastatic melanoma. Global revenue for Opdualag grew nearly 4.7-fold between 2022 and 2025, with the U.S. accounting for approximately 88% of total revenue, demonstrating strong physician adoption and establishing a billion-dollar market opportunity. Bristol Myers Squibb is actively pursuing lifecycle expansion across additional solid tumors, including Phase III trials for first-line non-small cell lung cancer, while competitors including Gilead Sciences/Arcus, Novartis, Compugen, and Hummingbird Bioscience advance their own novel checkpoint inhibitors through clinical development.FinancialContent Business PageHummingbird Bioscience Wins APAC Trailblazer Award at 2026 Nebius AI Discovery AwardsHummingbird Bioscience won the Asia Pacific Trailblazer Award at the 2026 AI Discovery Awards hosted by Nebius, selected from 647 global submissions by an independent judging panel. The award recognizes the company's AI-first approach to drug discovery through its AI Molecular Medicine platform, which integrates patient biology, drug design, and clinical development to advance multiple clinical-stage therapies. The company's pipeline includes HMBD-001 (HER3-targeting monoclonal antibody in Phase Ib/II trials) and HMBD-501 (HER3-targeting antibody-drug conjugate in Phase I trials), with operations based in Singapore and clinical strategy spanning Asia, the United States, and Europe.BioSpaceHummingbird Bioscience Wins APAC Trailblazer Award at 2026 Nebius AI Discovery AwardsHummingbird Bioscience won the Asia Pacific Trailblazer Award at the 2026 AI Discovery Awards hosted by Nebius, selected from 647 global submissions. The company's AI Molecular Medicine platform has generated multiple clinical-stage therapies and is validated by strategic partnerships and out-licensing transactions.